´ëÇ¥¼Àû
°¡¿îÀ» ¹þÀÚ (ÀÇÇÐ ¼¼»ó°ú ¸¸³ª´Ù)
- ÀúÀÚ(±Û)ÀÓÀçÁØ
- ÃâÆÇ»ç2011³â
- ¹ßÇàÀÏÀÏÁ¶°¢
Æä°áÇÙ Ä¡·á ±ÇÀ§ÀÚ, ȯÀÚ À§ÇÑ Å¬¸®´Ð ¿î¿µ
| Á¦ ¸ñ | Tuberculosis |
|---|---|
| ÃâÆÇ»ç | Springer |
| ¹ßÇàÀÏ | 2004³â |
| Á¦ ¸ñ | Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense |
|---|---|
| ¹ßÇ¥³âµµ | 2017-02 |
| ¹ßÇ¥Áö | CLINICAL INFECTIOUS DISEASES |
| Á¦ ¸ñ | Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : a prospective cohort study |
|---|---|
| ¹ßÇ¥³âµµ | 2017-01 |
| ¹ßÇ¥Áö | BMC PULMONARY MEDICINE |
| Á¦ ¸ñ | Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial |
|---|---|
| ¹ßÇ¥³âµµ | 2017-01 |
| ¹ßÇ¥Áö | TRIALS |
| Á¦ ¸ñ | Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist |
|---|---|
| ¹ßÇ¥³âµµ | 2017-05 |
| ¹ßÇ¥Áö | Annals of the American Thoracic Society |
| Á¦ ¸ñ | Etiquette for medical students' email communication with faculty members: a single-institution study |
|---|---|
| ¹ßÇ¥³âµµ | 2016-04 |
| ¹ßÇ¥Áö | BMC MEDICAL EDUCATION |
| Á¦ ¸ñ | Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes |
|---|---|
| ¹ßÇ¥³âµµ | 2016-03 |
| ¹ßÇ¥Áö | Annals of the American Thoracic Society |
| Á¦ ¸ñ | Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis |
|---|---|
| ¹ßÇ¥³âµµ | 2016-01 |
| ¹ßÇ¥Áö | INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES |

¼¿ï´ëº´¿øÀº º»¿øÀ» ºñ·ÔÇÑ ¾î¸°À̺´¿ø, ¾Ïº´¿ø, ÀÇ»ý¸í¿¬±¸¿øÀ¸·Î ±¸¼ºµÅ ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î 1786º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 540¿© ¸íÀÇ ±³¼ö¿Í 5400¿© ¸íÀÇ Á÷¿øÀÌ ÇÏ·ç Æò±Õ 1700¿© ¸íÀÇ ÀÔ¿øÈ¯ÀÚ¿Í 8600¸íÀÌ ³Ñ´Â ¿Ü·¡È¯ÀÚ¸¦ µ¹º¸°í ÀÖ´Ù. ¼¼°èÀû ÷´Ü Áø·á ¿µ¿ªÀ» Áö¼ÓÀûÀ¸·Î È®º¸ÇÔÀ¸·Î½á ÃÖ»óÀÇ Áø·á ¼ºñ½º¸¦ Á¦°øÇϰí, ¿ì¸®³ª¶ó ÀÇ·á ¼±ÁøÈ¸¦ Ãß±¸ÇÏ´Â Á¤Ã¥ Çù·Â º´¿øÀÌ´Ù.
¼¿ïƯº°½Ã Á¾·Î±¸ ´ëÇзΠ101